Faculty Appointments
Associate Professor of Medicine
Education
Ph.D., Cancer Biology, Vanderbilt University, Nashville, TennesseeB.S., Lafayette College, Easton, Pennsylvania
Office Address
Vanderbilt University
771 Preston Research Building
2220 Pierce Avenue
Nashville, TN 37232
771 Preston Research Building
2220 Pierce Avenue
Nashville, TN 37232
Research Description
Dr. Dahlman is Associate Professor of Medicine (Division of Hematology/Oncology) at Vanderbilt University Medical Center, Assistant Director of Cancer Research Training and Education at the Vanderbilt-Ingram Cancer Center (VICC), and Co-Director of the 3rd and 4th year undergraduate medical education curriculum at Vanderbilt University School of Medicine. Dr. Dahlman also serves as co-Director of the Research Education Core of the Meharry-Vanderbilt-Tennessee State University Cancer Partnership, Director of the VERTICAL post-baccalaureate, the V-EXCEL undergraduate, and the VISTO medical student cancer research programs at VICC. For 15 years, Dr. Dahlman also directed the Innovative Translational Research Shared Resource, a collaborative laboratory with the goal of understanding mechanisms of response and resistance to novel anti-cancer therapies. Nationally, Dr. Dahlman is Past-President of the Association of Biochemistry Educators and is a Board Member for the International Association of Medical Science Educators (IAMSE). She was awarded the Denis M. O’Day award for Team Implemented Curriculum and the Dean Bonnie M. Miller Immersion Award from VUSM, the Early Career Award for Excellence in Teaching and Innovation from IAMSE, and the Stephen Abrahamson Award for Innovation from the Keck School of Medicine. Dr. Dahlman’s area of expertise is in foundational science integration in undergraduate medical education curricula, professional identity formation, and program evaluation. She has formally and informally mentored several faculty and medical students in medical education.
Research Keywords
Cancer, Translational Research, Clinical Research, Education, Oncology, Integration, Shared Resource, Core
Publications
Martinez AF, Schafer JC, Canning J, O'Neal J, Dahlman KB. Core Exchange: A Professional Development Program for Shared Resource Personnel. J Biomol Tech. 2024 Apr 4/30/2024; 35(1): PMID: 39239237, PMCID: PMC11373896, PII: 3fc1f5fe.1eb341de, DOI: 10.7171/3fc1f5fe.1eb341de, ISSN: 1943-4731.
Franklin DS, Richardson C, Eisenmann KM, Simmons JM, Fong SFT, Spicer DB, Sadik A, Dahlman KB. Teaching Biochemistry to Students of Dentistry, Medicine, and Pharmacy 9th International Conference of the Association of Biochemistry Educators (ABE) Kiawah Island, South Carolina, April 30-May 4, 2023. Med Sci Educ. 2023 Dec; 33(6): 1439-44. PMID: 38188374, PMCID: PMC10767168, PII: 1889, DOI: 10.1007/s40670-023-01889-7, ISSN: 2156-8650.
Brooks JV, Dickinson BL, Quesnelle KM, Bonaminio GA, Chalk-Wilayto J, Dahlman KB, Fulton TB, Hyland KM, Kruidering M, Osheroff N, Tuan RL, Ho MJ. Professional Identity Formation of Basic Science Medical Educators: A Qualitative Study of Identity Supports and Threats. Acad Med [print-electronic]. 2023 Nov 11/1/2023; 98(11S): S14-S23-S23. PMID: 37556802, PMCID: PMC10657385, PII: 00001888-202311001-00006, DOI: 10.1097/ACM.0000000000005354, ISSN: 1938-808X.
Makhoul AE, Kertai MD, Powers J, Dahlman KB, Suojanen K. Training Tomorrow's Physicians in Value Conscious Medicine. Acad Med [print-electronic]. 2023 Jul 7/1/2023; 98(7): 795-9. PMID: 36693144, PII: 00001888-202307000-00027, DOI: 10.1097/ACM.0000000000005160, ISSN: 1938-808X.
Cardin DB, Gilbert J, Whisenant JG, Ayers GD, Jalikis F, Dahlman KB, O'Neal JF, Revetta F, Shi C, Berlin J. Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma. Clin Colorectal Cancer [print-electronic]. 2022 Sep; 21(3): 236-43. PMID: 35450836, PII: S1533-0028(22)00039-1, DOI: 10.1016/j.clcc.2022.03.003, ISSN: 1938-0674.
Yeh AC, Varelias A, Reddy A, Barone SM, Olver SD, Chilson K, Onstad LE, Ensbey KS, Henden AS, Samson L, Jaeger CA, Bi T, Dahlman KB, Kim TK, Zhang P, Degli-Esposti MA, Newell EW, Jagasia MH, Irish JM, Lee SJ, Hill GR. CMV exposure drives long-term CD57+ CD4 memory T-cell inflation following allogeneic stem cell transplant. Blood. 2021 Dec 12/30/2021; 138(26): 2874-85. PMID: 34115118, PMCID: PMC8718626, PII: S0006-4971(21)01162-9, DOI: 10.1182/blood.2020009492, ISSN: 1528-0020.
Seagroves TN, Bagarozzi D, Bagchi P, Boukli NM, Browner N, Colton-Lee F, Constable S, Dahlman KB, Griffiths L, Mesa TE, Somasundaram T. The Eighth Annual Meeting of the Southeastern Association of Shared Resources (SEASR), Atlanta, GA, June 10-11, 2021. J Biomol Tech. 2021 Dec 12/15/2021; 32(4): PMID: 35837271, PMCID: PMC9258611, PII: 3fc1f5fe.ea38010c, DOI: 10.7171/3fc1f5fe.ea38010c, ISSN: 1943-4731.
Simmons JM, Franklin DS, Dahlman KB, Symes K, Viselli SM, Diaz-Cruz ES, Fong SFT, Spicer DB. Teaching Biochemistry to Students of Dentistry, Medicine, and Pharmacy: 8th International Conference of the Association of Biochemistry Educators (ABE) Virtual Conference, May 3-7, 2021. Med Sci Educ. 2021 Dec; 31(6): 2125-8. PMID: 34567835, PMCID: PMC8452131, PII: 1402, DOI: 10.1007/s40670-021-01402-y, ISSN: 2156-8650.
Hu JR, Patel A, Huang S, Su YR, Dahlman KB, Tomasek K, Zhang Y, O'Neil RT, O'Neal JF, Turker I, Johnson DB, Salem JE, Moslehi JJ, Oluwole O. High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy. Clin Hematol Int. 2021 Sep; 3(3): 96-102. PMID: 34820614, PMCID: PMC8486972, PII: CHI-3-3-96, DOI: 10.2991/chi.k.210718.001, ISSN: 2590-0048.
Zivanov C, Li X, Shah KP, Estrada L, Cutrer WB, Hooks M, Keedy V, Dahlman KB. Precision Cancer Medicine: Dynamic Learning of Cancer Biology in a Clinically Meaningful Context. Med Sci Educ. 2021 Jun; 31(3): 1029-42. PMID: 34457947, PMCID: PMC8368858, PII: 1267, DOI: 10.1007/s40670-021-01267-1, ISSN: 2156-8650.
Shiuan E, Reddy A, Dudzinski SO, Lim AR, Sugiura A, Hongo R, Young K, Liu XD, Smith CC, O'Neal J, Dahlman KB, McAlister R, Chen B, Ruma K, Roscoe N, Bender J, Ward J, Kim JY, Vaupel C, Bordeaux J, Ganesan S, Mayer TM, Riedlinger GM, Vincent BG, Davis NB, Haake SM, Rathmell JC, Jonasch E, Rini BI, Rathmell WK, Beckermann KE. Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. Cancers (Basel). 2021 Mar 3/23/2021; 13(6): PMID: 33806963, PMCID: PMC8004696, PII: cancers13061475, DOI: 10.3390/cancers13061475, ISSN: 2072-6694.
Dahlman KB, Bagarozzi D, Bagchi P, Blum D, Boukli NM, Colton-Lee F, Constable S, Seagroves TN, Somasundaram T. "Making the Right Decisions: Adapting to Emerging Needs": The 7th Annual Meeting of the Southeastern Association of Shared Resources, Atlanta, GA, USA, June 12-14, 2019. J Biomol Tech. 2020 Dec; 31(4): 165-7. PMID: 33223965, PMCID: PMC7660625, PII: JBT_2020-3104-007, DOI: 10.7171/jbt.2020-3104-007, ISSN: 1943-4731.
Shattuck-Brandt RL, Chen SC, Murray E, Johnson CA, Crandall H, O'Neal JF, Al-Rohil RN, Nebhan CA, Bharti V, Dahlman KB, Ayers GD, Yan C, Kelley MC, Kauffmann RM, Hooks M, Grau A, Johnson DB, Vilgelm AE, Richmond A. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. Clin Cancer Res [print-electronic]. 2020 Jul 7/15/2020; 26(14): 3803-18. PMID: 32234759, PMCID: PMC7367743, PII: 1078-0432.CCR-19-1895, DOI: 10.1158/1078-0432.CCR-19-1895, ISSN: 1557-3265.
Gallant JN, Sewell A, Almodovar K, Wang Q, Dahlman KB, Abramson RG, Kapp ME, Brown BT, Boyd KL, Gilbert J, Cohen DN, Yarbrough WG, Zhao Z, Lovly CM. Genomic landscape of a metastatic malignant proliferating tricholemmal tumor and its response to PI3K inhibition. NPJ Precis Oncol. 2019; 3: 5. PMID: 30793038, PMCID: PMC6377617, PII: 77, DOI: 10.1038/s41698-019-0077-2, ISSN: 2397-768X.
Johnson DB, Dahlman KB. Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition. Clin Cancer Res [print-electronic]. 2018 Dec 12/15/2018; 24(24): 6107-9. PMID: 30042206, PMCID: PMC6295213, PII: 1078-0432.CCR-18-1795, DOI: 10.1158/1078-0432.CCR-18-1795, ISSN: 1557-3265.
Doxie DB, Greenplate AR, Gandelman JS, Diggins KE, Roe CE, Dahlman KB, Sosman JA, Kelley MC, Irish JM. BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors. Pigment Cell Melanoma Res [print-electronic]. 2018 Nov; 31(6): 708-19. PMID: 29778085, PMCID: PMC6188784, DOI: 10.1111/pcmr.12712, ISSN: 1755-148X.
Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, Matusow B, Bartenstein M, Polishchuk V, Johnson DB, Bhagat TD, Shellooe R, Burton E, Tsai J, Zhang C, Habets G, Greally JM, Yu Y, Kenny PA, Fields GB, Pradhan K, Stanley ER, Bernstein E, Bollag G, Gavathiotis E, West BL, Sosman JA, Verma AK. The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. JCI Insight. 2018 Jul 7/26/2018; 3(14): PMID: 30046005, PMCID: PMC6124424, PII: 120422, DOI: 10.1172/jci.insight.120422, ISSN: 2379-3708.
Dahlman KB, Weinger MB, Lomis KD, Nanney L, Osheroff N, Moore DE, Estrada L, Cutrer WB. Integrating Foundational Sciences in a Clinical Context in the Post-Clerkship Curriculum. Med Sci Educ [print-electronic]. 2018 Mar; 28(1): 145-54. PMID: 29632705, PMCID: PMC5889049, ISSN: 2156-8650.
Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. Cancer Discov [print-electronic]. 2017 Nov; 7(11): 1248-65. PMID: 28864476, PII: 2159-8290.CD-17-0401, DOI: 10.1158/2159-8290.CD-17-0401, ISSN: 2159-8290.
Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. Cancer Discov [print-electronic]. 2017 Nov; 7(11): 1248-65. PMID: 28864476, PII: 2159-8290.CD-17-0401, DOI: 10.1158/2159-8290.CD-17-0401, ISSN: 2159-8290.
Idrees K, Padmanabhan C, Liu E, Guo Y, Gonzalez RS, Berlin J, Dahlman KB, Beauchamp RD, Shi C. Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. J Surg Oncol [print-electronic]. 2017 Sep 9/20/2017; PMID: 28940307, DOI: 10.1002/jso.24834, ISSN: 1096-9098.
Idrees K, Padmanabhan C, Liu E, Guo Y, Gonzalez RS, Berlin J, Dahlman KB, Beauchamp RD, Shi C. Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. J Surg Oncol [print-electronic]. 2017 Sep 9/20/2017; PMID: 28940307, DOI: 10.1002/jso.24834, ISSN: 1096-9098.
Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PE. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Mol Oncol [print-electronic]. 2017 Apr; 11(4): 405-21. PMID: 28188683, PMCID: PMC5378659, DOI: 10.1002/1878-0261.12044, ISSN: 1878-0261.
Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PE. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Mol Oncol [print-electronic]. 2017 Apr; 11(4): 405-21. PMID: 28188683, PMCID: PMC5378659, DOI: 10.1002/1878-0261.12044, ISSN: 1878-0261.
Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. Invest New Drugs [print-electronic]. 2017 Feb; 35(1): 95-104. PMID: 27853997, PMCID: PMC5306261, PII: 10.1007/s10637-016-0406-z, DOI: 10.1007/s10637-016-0406-z, ISSN: 1573-0646.
Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. Invest New Drugs [print-electronic]. 2017 Feb; 35(1): 95-104. PMID: 27853997, PMCID: PMC5306261, PII: 10.1007/s10637-016-0406-z, DOI: 10.1007/s10637-016-0406-z, ISSN: 1573-0646.
Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene [print-electronic]. 2016 Mar 3/10/2016; 35(10): 1225-35. PMID: 26073081, PMCID: PMC4679729, PII: onc2015188, DOI: 10.1038/onc.2015.188, ISSN: 1476-5594.
Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene [print-electronic]. 2016 Mar 3/10/2016; 35(10): 1225-35. PMID: 26073081, PMCID: PMC4679729, PII: onc2015188, DOI: 10.1038/onc.2015.188, ISSN: 1476-5594.
Mudigonda TV, Wyman K, Spigel DR, Dahlman KB, Greco FA, Puzanov I, Kelley MC, Hainsworth JD, Sosman JA, Johnson DB. A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma [letter]. Pigment Cell Melanoma Res [print-electronic]. 2016 Jan; 29(1): 101-3. PMID: 26176864, DOI: 10.1111/pcmr.12394, ISSN: 1755-148X.
Mudigonda TV, Wyman K, Spigel DR, Dahlman KB, Greco FA, Puzanov I, Kelley MC, Hainsworth JD, Sosman JA, Johnson DB. A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma [letter]. Pigment Cell Melanoma Res [print-electronic]. 2016 Jan; 29(1): 101-3. PMID: 26176864, DOI: 10.1111/pcmr.12394, ISSN: 1755-148X.
Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, Sosman JA, Ribas A, Lo RS. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 2015 Sep 9/10/2015; 162(6): 1271-85. PMID: 26359985, PMCID: PMC4821508, PII: S0092-8674(15)01040-5, DOI: 10.1016/j.cell.2015.07.061, ISSN: 1097-4172.
Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, Sosman JA, Ribas A, Lo RS. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 2015 Sep 9/10/2015; 162(6): 1271-85. PMID: 26359985, PMCID: PMC4821508, PII: S0092-8674(15)01040-5, DOI: 10.1016/j.cell.2015.07.061, ISSN: 1097-4172.
McGirt LY, Jia P, Baerenwald DA, Duszynski RJ, Dahlman KB, Zic JA, Zwerner JP, Hucks D, Dave U, Zhao Z, Eischen CM. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood [print-electronic]. 2015 Jul 7/23/2015; 126(4): 508-19. PMID: 26082451, PMCID: PMC4513251, PII: blood-2014-11-611194, DOI: 10.1182/blood-2014-11-611194, ISSN: 1528-0020.
McGirt LY, Jia P, Baerenwald DA, Duszynski RJ, Dahlman KB, Zic JA, Zwerner JP, Hucks D, Dave U, Zhao Z, Eischen CM. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood [print-electronic]. 2015 Jul 7/23/2015; 126(4): 508-19. PMID: 26082451, PMCID: PMC4513251, PII: blood-2014-11-611194, DOI: 10.1182/blood-2014-11-611194, ISSN: 1528-0020.
Johnson AS, Crandall H, Dahlman K, Kelley MC. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma. J. Am. Coll. Surg [print-electronic]. 2015 Apr; 220(4): 581-93.e1. PMID: 25797743, PII: S1072-7515(15)00074-5, DOI: 10.1016/j.jamcollsurg.2014.12.057, ISSN: 1879-1190.
Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell [print-electronic]. 2015 Feb 2/9/2015; 27(2): 240-56. PMID: 25600339, PMCID: PMC4326539, PII: S1535-6108(14)00469-3, DOI: 10.1016/j.ccell.2014.11.018, ISSN: 1878-3686.
Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell [print-electronic]. 2015 Feb 2/9/2015; 27(2): 240-56. PMID: 25600339, PMCID: PMC4326539, PII: S1535-6108(14)00469-3, DOI: 10.1016/j.ccell.2014.11.018, ISSN: 1878-3686.
Iams WT, Hames ML, Tsai JP, Dahlman KB, Talbott MS, Richards KL, Reddy NM. Increased serum tumor necrosis factor a levels in patients with lenalidomide-induced hypothyroidism. Exp. Hematol [print-electronic]. 2015 Feb; 43(2): 74-8. PMID: 25448491, PMCID: PMC5002942, PII: S0301-472X(14)00715-2, DOI: 10.1016/j.exphem.2014.10.009, ISSN: 1873-2399.
Iams WT, Hames ML, Tsai JP, Dahlman KB, Talbott MS, Richards KL, Reddy NM. Increased serum tumor necrosis factor a levels in patients with lenalidomide-induced hypothyroidism. Exp. Hematol [print-electronic]. 2015 Feb; 43(2): 74-8. PMID: 25448491, PMCID: PMC5002942, PII: S0301-472X(14)00715-2, DOI: 10.1016/j.exphem.2014.10.009, ISSN: 1873-2399.
Xia J, Jia P, Hutchinson KE, Dahlman KB, Johnson D, Sosman J, Pao W, Zhao Z. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol. Cancer Ther [print-electronic]. 2014 Jul; 13(7): 1918-28. PMID: 24755198, PMCID: PMC4090262, PII: 1535-7163.MCT-13-0804, DOI: 10.1158/1535-7163.MCT-13-0804, ISSN: 1538-8514.
Xia J, Jia P, Hutchinson KE, Dahlman KB, Johnson D, Sosman J, Pao W, Zhao Z. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol. Cancer Ther [print-electronic]. 2014 Jul; 13(7): 1918-28. PMID: 24755198, PMCID: PMC4090262, PII: 1535-7163.MCT-13-0804, DOI: 10.1158/1535-7163.MCT-13-0804, ISSN: 1538-8514.
Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.
Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Res. Treat [print-electronic]. 2014 Jun; 145(2): 389-99. PMID: 24722917, PMCID: PMC4046906, DOI: 10.1007/s10549-014-2945-3, ISSN: 1573-7217.
Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Res. Treat [print-electronic]. 2014 Jun; 145(2): 389-99. PMID: 24722917, PMCID: PMC4046906, DOI: 10.1007/s10549-014-2945-3, ISSN: 1573-7217.
Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin. Cancer Res [print-electronic]. 2014 May 5/1/2014; 20(9): 2264-75. PMID: 24599935, PMCID: PMC4008689, PII: 1078-0432.CCR-13-1591, DOI: 10.1158/1078-0432.CCR-13-1591, ISSN: 1078-0432.
Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin. Cancer Res [print-electronic]. 2014 May 5/1/2014; 20(9): 2264-75. PMID: 24599935, PMCID: PMC4008689, PII: 1078-0432.CCR-13-1591, DOI: 10.1158/1078-0432.CCR-13-1591, ISSN: 1078-0432.
Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov [print-electronic]. 2014 Jan; 4(1): 80-93. PMID: 24265155, PMCID: PMC3936420, DOI: 10.1158/2159-8290.CD-13-0642, ISSN: 2159-8290.
Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov [print-electronic]. 2014 Jan; 4(1): 80-93. PMID: 24265155, PMCID: PMC3936420, DOI: 10.1158/2159-8290.CD-13-0642, ISSN: 2159-8290.
Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Res [print-electronic]. 2013 Sep; 23(9): 1434-45. PMID: 23733853, PMCID: PMC3759720, PII: gr.152322.112, DOI: 10.1101/gr.152322.112, ISSN: 1549-5469.
Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Res [print-electronic]. 2013 Sep; 23(9): 1434-45. PMID: 23733853, PMCID: PMC3759720, PII: gr.152322.112, DOI: 10.1101/gr.152322.112, ISSN: 1549-5469.
Wang Q, Jia P, Li F, Chen H, Ji H, Hucks D, Dahlman KB, Pao W, Zhao Z. Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Genome Med. 2013; 5(10): 91. PMID: 24112718, PMCID: PMC3971343, PII: gm495, DOI: 10.1186/gm495, ISSN: 1756-994X.
Wang Q, Jia P, Li F, Chen H, Ji H, Hucks D, Dahlman KB, Pao W, Zhao Z. Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Genome Med. 2013; 5(10): 91. PMID: 24112718, PMCID: PMC3971343, PII: gm495, DOI: 10.1186/gm495, ISSN: 1756-994X.
Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, Netterville JL, Vnencak-Jones CL, Sosman JA, Ribas A, Zhao Z, Pao W. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov [print-electronic]. 2012 Sep; 2(9): 791-7. PMID: 22798288, PMCID: PMC3449158, PII: 2159-8290.CD-12-0097, DOI: 10.1158/2159-8290.CD-12-0097, ISSN: 2159-8290.
Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov [print-electronic]. 2012 May; 2(5): 414-24. PMID: 22588879, PMCID: PMC3594852, PII: 2159-8290.CD-12-0022, DOI: 10.1158/2159-8290.CD-12-0022, ISSN: 2159-8290.
Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A. RAF265 inhibits the growth of advanced human melanoma tumors. Clin. Cancer Res [print-electronic]. 2012 Apr 4/15/2012; 18(8): 2184-98. PMID: 22351689, PMCID: PMC3724517, PII: 1078-0432.CCR-11-1122, DOI: 10.1158/1078-0432.CCR-11-1122, ISSN: 1078-0432.
Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012; 3: 724. PMID: 22395615, PMCID: PMC3530385, PII: ncomms1727, DOI: 10.1038/ncomms1727, ISSN: 2041-1723.
Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS ONE [print-electronic]. 2012; 7(4): e35309. PMID: 22536370, PMCID: PMC3335021, PII: PONE-D-12-03589, DOI: 10.1371/journal.pone.0035309, ISSN: 1932-6203.
Dahlman KB, Parker JS, Shamu T, Hieronymus H, Chapinski C, Carver B, Chang K, Hannon GJ, Sawyers CL. Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. PLoS ONE [print-electronic]. 2012; 7(4): e34414. PMID: 22509301, PMCID: PMC3324507, PII: PONE-D-11-18538, DOI: 10.1371/journal.pone.0034414, ISSN: 1932-6203.
Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Dec 12/15/2011; 480(7377): 387-90. PMID: 22113612, PMCID: PMC3266695, PII: nature10662, DOI: 10.1038/nature10662, ISSN: 1476-4687.
Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL. FAS and NF-¿B signalling modulate dependence of lung cancers on mutant EGFR. Nature. 2011 Mar 3/24/2011; 471(7339): 523-6. PMID: 21430781, PMCID: PMC3541675, PII: nature09870, DOI: 10.1038/nature09870, ISSN: 1476-4687.
Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010 Dec 12/14/2010; 18(6): 683-95. PMID: 21156289, PMCID: PMC3026446, PII: S1535-6108(10)00484-8, DOI: 10.1016/j.ccr.2010.11.023, ISSN: 1878-3686.
Brown KA, Ham AJ, Clark CN, Meller N, Law BK, Chytil A, Cheng N, Pietenpol JA, Moses HL. Identification of novel Smad2 and Smad3 associated proteins in response to TGF-beta1. J. Cell. Biochem. 2008 Oct 10/1/2008; 105(2): 596-611. PMID: 18729074, PMCID: PMC2700048, DOI: 10.1002/jcb.21860, ISSN: 1097-4644.
Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J. Cell. Biochem. 2007 May 5/1/2007; 101(1): 9-33. PMID: 17340614, DOI: 10.1002/jcb.21255, ISSN: 0730-2312.
Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, Moses HL, Cheng N. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol. Ther. 2007 Apr; 6(4): 561-70. PMID: 17495520, PMCID: PMC3395216, PII: 3851, ISSN: 1538-4047.
Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res. 2006 Aug 8/1/2006; 66(15): 7589-97. PMID: 16885358, PII: 66/15/7589, DOI: 10.1158/0008-5472.CAN-06-2020, ISSN: 0008-5472.
Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene. 2005 Jul 7/28/2005; 24(32): 5053-68. PMID: 15856015, PMCID: PMC3074577, PII: 1208685, DOI: 10.1038/sj.onc.1208685, ISSN: 0950-9232.
Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia. 2004 Sep; 6(5): 603-10. PMID: 15548370, PMCID: PMC1531665, DOI: 10.1593/neo.04241, ISSN: 1522-8002.
Brown K, Bhowmick NA. Linking TGF-beta-mediated Cdc25A inhibition and cytoskeletal regulation through RhoA/p160(ROCK) signaling. Cell Cycle [print-electronic]. 2004 Apr; 3(4): 408-10. PMID: 14752278, PII: 778, ISSN: 1538-4101.
Brown KA, Aakre ME, Gorska AE, Price JO, Eltom SE, Pietenpol JA, Moses HL. Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res [print-electronic]. 2004; 6(3): R215-31. PMID: 15084245, PMCID: PMC400675, PII: bcr778, DOI: 10.1186/bcr778, ISSN: 1465-542X.
Brown KA, Roberts RL, Arteaga CL, Law BK. Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein. Breast Cancer Res [print-electronic]. 2004; 6(2): R130-9. PMID: 14979923, PMCID: PMC400660, PII: bcr762, DOI: 10.1186/bcr762, ISSN: 1465-542X.
Bhowmick NA, Ghiassi M, Aakre M, Brown K, Singh V, Moses HL. TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proc. Natl. Acad. Sci. U.S.A [print-electronic]. 2003 Dec 12/23/2003; 100(26): 15548-53. PMID: 14657354, PMCID: PMC307605, PII: 2536483100, DOI: 10.1073/pnas.2536483100, ISSN: 0027-8424.
Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem. Biophys. Res. Commun. 1997 Dec 12/18/1997; 241(2): 270-4. PMID: 9425261, PII: S0006-291X(97)97798-6, DOI: 10.1006/bbrc.1997.7798, ISSN: 0006-291X.
Franklin DS, Richardson C, Eisenmann KM, Simmons JM, Fong SFT, Spicer DB, Sadik A, Dahlman KB. Teaching Biochemistry to Students of Dentistry, Medicine, and Pharmacy 9th International Conference of the Association of Biochemistry Educators (ABE) Kiawah Island, South Carolina, April 30-May 4, 2023. Med Sci Educ. 2023 Dec; 33(6): 1439-44. PMID: 38188374, PMCID: PMC10767168, PII: 1889, DOI: 10.1007/s40670-023-01889-7, ISSN: 2156-8650.
Brooks JV, Dickinson BL, Quesnelle KM, Bonaminio GA, Chalk-Wilayto J, Dahlman KB, Fulton TB, Hyland KM, Kruidering M, Osheroff N, Tuan RL, Ho MJ. Professional Identity Formation of Basic Science Medical Educators: A Qualitative Study of Identity Supports and Threats. Acad Med [print-electronic]. 2023 Nov 11/1/2023; 98(11S): S14-S23-S23. PMID: 37556802, PMCID: PMC10657385, PII: 00001888-202311001-00006, DOI: 10.1097/ACM.0000000000005354, ISSN: 1938-808X.
Makhoul AE, Kertai MD, Powers J, Dahlman KB, Suojanen K. Training Tomorrow's Physicians in Value Conscious Medicine. Acad Med [print-electronic]. 2023 Jul 7/1/2023; 98(7): 795-9. PMID: 36693144, PII: 00001888-202307000-00027, DOI: 10.1097/ACM.0000000000005160, ISSN: 1938-808X.
Cardin DB, Gilbert J, Whisenant JG, Ayers GD, Jalikis F, Dahlman KB, O'Neal JF, Revetta F, Shi C, Berlin J. Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma. Clin Colorectal Cancer [print-electronic]. 2022 Sep; 21(3): 236-43. PMID: 35450836, PII: S1533-0028(22)00039-1, DOI: 10.1016/j.clcc.2022.03.003, ISSN: 1938-0674.
Yeh AC, Varelias A, Reddy A, Barone SM, Olver SD, Chilson K, Onstad LE, Ensbey KS, Henden AS, Samson L, Jaeger CA, Bi T, Dahlman KB, Kim TK, Zhang P, Degli-Esposti MA, Newell EW, Jagasia MH, Irish JM, Lee SJ, Hill GR. CMV exposure drives long-term CD57+ CD4 memory T-cell inflation following allogeneic stem cell transplant. Blood. 2021 Dec 12/30/2021; 138(26): 2874-85. PMID: 34115118, PMCID: PMC8718626, PII: S0006-4971(21)01162-9, DOI: 10.1182/blood.2020009492, ISSN: 1528-0020.
Seagroves TN, Bagarozzi D, Bagchi P, Boukli NM, Browner N, Colton-Lee F, Constable S, Dahlman KB, Griffiths L, Mesa TE, Somasundaram T. The Eighth Annual Meeting of the Southeastern Association of Shared Resources (SEASR), Atlanta, GA, June 10-11, 2021. J Biomol Tech. 2021 Dec 12/15/2021; 32(4): PMID: 35837271, PMCID: PMC9258611, PII: 3fc1f5fe.ea38010c, DOI: 10.7171/3fc1f5fe.ea38010c, ISSN: 1943-4731.
Simmons JM, Franklin DS, Dahlman KB, Symes K, Viselli SM, Diaz-Cruz ES, Fong SFT, Spicer DB. Teaching Biochemistry to Students of Dentistry, Medicine, and Pharmacy: 8th International Conference of the Association of Biochemistry Educators (ABE) Virtual Conference, May 3-7, 2021. Med Sci Educ. 2021 Dec; 31(6): 2125-8. PMID: 34567835, PMCID: PMC8452131, PII: 1402, DOI: 10.1007/s40670-021-01402-y, ISSN: 2156-8650.
Hu JR, Patel A, Huang S, Su YR, Dahlman KB, Tomasek K, Zhang Y, O'Neil RT, O'Neal JF, Turker I, Johnson DB, Salem JE, Moslehi JJ, Oluwole O. High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy. Clin Hematol Int. 2021 Sep; 3(3): 96-102. PMID: 34820614, PMCID: PMC8486972, PII: CHI-3-3-96, DOI: 10.2991/chi.k.210718.001, ISSN: 2590-0048.
Zivanov C, Li X, Shah KP, Estrada L, Cutrer WB, Hooks M, Keedy V, Dahlman KB. Precision Cancer Medicine: Dynamic Learning of Cancer Biology in a Clinically Meaningful Context. Med Sci Educ. 2021 Jun; 31(3): 1029-42. PMID: 34457947, PMCID: PMC8368858, PII: 1267, DOI: 10.1007/s40670-021-01267-1, ISSN: 2156-8650.
Shiuan E, Reddy A, Dudzinski SO, Lim AR, Sugiura A, Hongo R, Young K, Liu XD, Smith CC, O'Neal J, Dahlman KB, McAlister R, Chen B, Ruma K, Roscoe N, Bender J, Ward J, Kim JY, Vaupel C, Bordeaux J, Ganesan S, Mayer TM, Riedlinger GM, Vincent BG, Davis NB, Haake SM, Rathmell JC, Jonasch E, Rini BI, Rathmell WK, Beckermann KE. Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. Cancers (Basel). 2021 Mar 3/23/2021; 13(6): PMID: 33806963, PMCID: PMC8004696, PII: cancers13061475, DOI: 10.3390/cancers13061475, ISSN: 2072-6694.
Dahlman KB, Bagarozzi D, Bagchi P, Blum D, Boukli NM, Colton-Lee F, Constable S, Seagroves TN, Somasundaram T. "Making the Right Decisions: Adapting to Emerging Needs": The 7th Annual Meeting of the Southeastern Association of Shared Resources, Atlanta, GA, USA, June 12-14, 2019. J Biomol Tech. 2020 Dec; 31(4): 165-7. PMID: 33223965, PMCID: PMC7660625, PII: JBT_2020-3104-007, DOI: 10.7171/jbt.2020-3104-007, ISSN: 1943-4731.
Shattuck-Brandt RL, Chen SC, Murray E, Johnson CA, Crandall H, O'Neal JF, Al-Rohil RN, Nebhan CA, Bharti V, Dahlman KB, Ayers GD, Yan C, Kelley MC, Kauffmann RM, Hooks M, Grau A, Johnson DB, Vilgelm AE, Richmond A. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. Clin Cancer Res [print-electronic]. 2020 Jul 7/15/2020; 26(14): 3803-18. PMID: 32234759, PMCID: PMC7367743, PII: 1078-0432.CCR-19-1895, DOI: 10.1158/1078-0432.CCR-19-1895, ISSN: 1557-3265.
Gallant JN, Sewell A, Almodovar K, Wang Q, Dahlman KB, Abramson RG, Kapp ME, Brown BT, Boyd KL, Gilbert J, Cohen DN, Yarbrough WG, Zhao Z, Lovly CM. Genomic landscape of a metastatic malignant proliferating tricholemmal tumor and its response to PI3K inhibition. NPJ Precis Oncol. 2019; 3: 5. PMID: 30793038, PMCID: PMC6377617, PII: 77, DOI: 10.1038/s41698-019-0077-2, ISSN: 2397-768X.
Johnson DB, Dahlman KB. Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition. Clin Cancer Res [print-electronic]. 2018 Dec 12/15/2018; 24(24): 6107-9. PMID: 30042206, PMCID: PMC6295213, PII: 1078-0432.CCR-18-1795, DOI: 10.1158/1078-0432.CCR-18-1795, ISSN: 1557-3265.
Doxie DB, Greenplate AR, Gandelman JS, Diggins KE, Roe CE, Dahlman KB, Sosman JA, Kelley MC, Irish JM. BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors. Pigment Cell Melanoma Res [print-electronic]. 2018 Nov; 31(6): 708-19. PMID: 29778085, PMCID: PMC6188784, DOI: 10.1111/pcmr.12712, ISSN: 1755-148X.
Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, Matusow B, Bartenstein M, Polishchuk V, Johnson DB, Bhagat TD, Shellooe R, Burton E, Tsai J, Zhang C, Habets G, Greally JM, Yu Y, Kenny PA, Fields GB, Pradhan K, Stanley ER, Bernstein E, Bollag G, Gavathiotis E, West BL, Sosman JA, Verma AK. The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. JCI Insight. 2018 Jul 7/26/2018; 3(14): PMID: 30046005, PMCID: PMC6124424, PII: 120422, DOI: 10.1172/jci.insight.120422, ISSN: 2379-3708.
Dahlman KB, Weinger MB, Lomis KD, Nanney L, Osheroff N, Moore DE, Estrada L, Cutrer WB. Integrating Foundational Sciences in a Clinical Context in the Post-Clerkship Curriculum. Med Sci Educ [print-electronic]. 2018 Mar; 28(1): 145-54. PMID: 29632705, PMCID: PMC5889049, ISSN: 2156-8650.
Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. Cancer Discov [print-electronic]. 2017 Nov; 7(11): 1248-65. PMID: 28864476, PII: 2159-8290.CD-17-0401, DOI: 10.1158/2159-8290.CD-17-0401, ISSN: 2159-8290.
Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. Cancer Discov [print-electronic]. 2017 Nov; 7(11): 1248-65. PMID: 28864476, PII: 2159-8290.CD-17-0401, DOI: 10.1158/2159-8290.CD-17-0401, ISSN: 2159-8290.
Idrees K, Padmanabhan C, Liu E, Guo Y, Gonzalez RS, Berlin J, Dahlman KB, Beauchamp RD, Shi C. Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. J Surg Oncol [print-electronic]. 2017 Sep 9/20/2017; PMID: 28940307, DOI: 10.1002/jso.24834, ISSN: 1096-9098.
Idrees K, Padmanabhan C, Liu E, Guo Y, Gonzalez RS, Berlin J, Dahlman KB, Beauchamp RD, Shi C. Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. J Surg Oncol [print-electronic]. 2017 Sep 9/20/2017; PMID: 28940307, DOI: 10.1002/jso.24834, ISSN: 1096-9098.
Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PE. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Mol Oncol [print-electronic]. 2017 Apr; 11(4): 405-21. PMID: 28188683, PMCID: PMC5378659, DOI: 10.1002/1878-0261.12044, ISSN: 1878-0261.
Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PE. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Mol Oncol [print-electronic]. 2017 Apr; 11(4): 405-21. PMID: 28188683, PMCID: PMC5378659, DOI: 10.1002/1878-0261.12044, ISSN: 1878-0261.
Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. Invest New Drugs [print-electronic]. 2017 Feb; 35(1): 95-104. PMID: 27853997, PMCID: PMC5306261, PII: 10.1007/s10637-016-0406-z, DOI: 10.1007/s10637-016-0406-z, ISSN: 1573-0646.
Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. Invest New Drugs [print-electronic]. 2017 Feb; 35(1): 95-104. PMID: 27853997, PMCID: PMC5306261, PII: 10.1007/s10637-016-0406-z, DOI: 10.1007/s10637-016-0406-z, ISSN: 1573-0646.
Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene [print-electronic]. 2016 Mar 3/10/2016; 35(10): 1225-35. PMID: 26073081, PMCID: PMC4679729, PII: onc2015188, DOI: 10.1038/onc.2015.188, ISSN: 1476-5594.
Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene [print-electronic]. 2016 Mar 3/10/2016; 35(10): 1225-35. PMID: 26073081, PMCID: PMC4679729, PII: onc2015188, DOI: 10.1038/onc.2015.188, ISSN: 1476-5594.
Mudigonda TV, Wyman K, Spigel DR, Dahlman KB, Greco FA, Puzanov I, Kelley MC, Hainsworth JD, Sosman JA, Johnson DB. A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma [letter]. Pigment Cell Melanoma Res [print-electronic]. 2016 Jan; 29(1): 101-3. PMID: 26176864, DOI: 10.1111/pcmr.12394, ISSN: 1755-148X.
Mudigonda TV, Wyman K, Spigel DR, Dahlman KB, Greco FA, Puzanov I, Kelley MC, Hainsworth JD, Sosman JA, Johnson DB. A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma [letter]. Pigment Cell Melanoma Res [print-electronic]. 2016 Jan; 29(1): 101-3. PMID: 26176864, DOI: 10.1111/pcmr.12394, ISSN: 1755-148X.
Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, Sosman JA, Ribas A, Lo RS. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 2015 Sep 9/10/2015; 162(6): 1271-85. PMID: 26359985, PMCID: PMC4821508, PII: S0092-8674(15)01040-5, DOI: 10.1016/j.cell.2015.07.061, ISSN: 1097-4172.
Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, Sosman JA, Ribas A, Lo RS. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 2015 Sep 9/10/2015; 162(6): 1271-85. PMID: 26359985, PMCID: PMC4821508, PII: S0092-8674(15)01040-5, DOI: 10.1016/j.cell.2015.07.061, ISSN: 1097-4172.
McGirt LY, Jia P, Baerenwald DA, Duszynski RJ, Dahlman KB, Zic JA, Zwerner JP, Hucks D, Dave U, Zhao Z, Eischen CM. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood [print-electronic]. 2015 Jul 7/23/2015; 126(4): 508-19. PMID: 26082451, PMCID: PMC4513251, PII: blood-2014-11-611194, DOI: 10.1182/blood-2014-11-611194, ISSN: 1528-0020.
McGirt LY, Jia P, Baerenwald DA, Duszynski RJ, Dahlman KB, Zic JA, Zwerner JP, Hucks D, Dave U, Zhao Z, Eischen CM. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood [print-electronic]. 2015 Jul 7/23/2015; 126(4): 508-19. PMID: 26082451, PMCID: PMC4513251, PII: blood-2014-11-611194, DOI: 10.1182/blood-2014-11-611194, ISSN: 1528-0020.
Johnson AS, Crandall H, Dahlman K, Kelley MC. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma. J. Am. Coll. Surg [print-electronic]. 2015 Apr; 220(4): 581-93.e1. PMID: 25797743, PII: S1072-7515(15)00074-5, DOI: 10.1016/j.jamcollsurg.2014.12.057, ISSN: 1879-1190.
Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell [print-electronic]. 2015 Feb 2/9/2015; 27(2): 240-56. PMID: 25600339, PMCID: PMC4326539, PII: S1535-6108(14)00469-3, DOI: 10.1016/j.ccell.2014.11.018, ISSN: 1878-3686.
Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell [print-electronic]. 2015 Feb 2/9/2015; 27(2): 240-56. PMID: 25600339, PMCID: PMC4326539, PII: S1535-6108(14)00469-3, DOI: 10.1016/j.ccell.2014.11.018, ISSN: 1878-3686.
Iams WT, Hames ML, Tsai JP, Dahlman KB, Talbott MS, Richards KL, Reddy NM. Increased serum tumor necrosis factor a levels in patients with lenalidomide-induced hypothyroidism. Exp. Hematol [print-electronic]. 2015 Feb; 43(2): 74-8. PMID: 25448491, PMCID: PMC5002942, PII: S0301-472X(14)00715-2, DOI: 10.1016/j.exphem.2014.10.009, ISSN: 1873-2399.
Iams WT, Hames ML, Tsai JP, Dahlman KB, Talbott MS, Richards KL, Reddy NM. Increased serum tumor necrosis factor a levels in patients with lenalidomide-induced hypothyroidism. Exp. Hematol [print-electronic]. 2015 Feb; 43(2): 74-8. PMID: 25448491, PMCID: PMC5002942, PII: S0301-472X(14)00715-2, DOI: 10.1016/j.exphem.2014.10.009, ISSN: 1873-2399.
Xia J, Jia P, Hutchinson KE, Dahlman KB, Johnson D, Sosman J, Pao W, Zhao Z. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol. Cancer Ther [print-electronic]. 2014 Jul; 13(7): 1918-28. PMID: 24755198, PMCID: PMC4090262, PII: 1535-7163.MCT-13-0804, DOI: 10.1158/1535-7163.MCT-13-0804, ISSN: 1538-8514.
Xia J, Jia P, Hutchinson KE, Dahlman KB, Johnson D, Sosman J, Pao W, Zhao Z. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol. Cancer Ther [print-electronic]. 2014 Jul; 13(7): 1918-28. PMID: 24755198, PMCID: PMC4090262, PII: 1535-7163.MCT-13-0804, DOI: 10.1158/1535-7163.MCT-13-0804, ISSN: 1538-8514.
Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.
Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Res. Treat [print-electronic]. 2014 Jun; 145(2): 389-99. PMID: 24722917, PMCID: PMC4046906, DOI: 10.1007/s10549-014-2945-3, ISSN: 1573-7217.
Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Res. Treat [print-electronic]. 2014 Jun; 145(2): 389-99. PMID: 24722917, PMCID: PMC4046906, DOI: 10.1007/s10549-014-2945-3, ISSN: 1573-7217.
Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin. Cancer Res [print-electronic]. 2014 May 5/1/2014; 20(9): 2264-75. PMID: 24599935, PMCID: PMC4008689, PII: 1078-0432.CCR-13-1591, DOI: 10.1158/1078-0432.CCR-13-1591, ISSN: 1078-0432.
Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin. Cancer Res [print-electronic]. 2014 May 5/1/2014; 20(9): 2264-75. PMID: 24599935, PMCID: PMC4008689, PII: 1078-0432.CCR-13-1591, DOI: 10.1158/1078-0432.CCR-13-1591, ISSN: 1078-0432.
Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov [print-electronic]. 2014 Jan; 4(1): 80-93. PMID: 24265155, PMCID: PMC3936420, DOI: 10.1158/2159-8290.CD-13-0642, ISSN: 2159-8290.
Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov [print-electronic]. 2014 Jan; 4(1): 80-93. PMID: 24265155, PMCID: PMC3936420, DOI: 10.1158/2159-8290.CD-13-0642, ISSN: 2159-8290.
Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Res [print-electronic]. 2013 Sep; 23(9): 1434-45. PMID: 23733853, PMCID: PMC3759720, PII: gr.152322.112, DOI: 10.1101/gr.152322.112, ISSN: 1549-5469.
Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Res [print-electronic]. 2013 Sep; 23(9): 1434-45. PMID: 23733853, PMCID: PMC3759720, PII: gr.152322.112, DOI: 10.1101/gr.152322.112, ISSN: 1549-5469.
Wang Q, Jia P, Li F, Chen H, Ji H, Hucks D, Dahlman KB, Pao W, Zhao Z. Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Genome Med. 2013; 5(10): 91. PMID: 24112718, PMCID: PMC3971343, PII: gm495, DOI: 10.1186/gm495, ISSN: 1756-994X.
Wang Q, Jia P, Li F, Chen H, Ji H, Hucks D, Dahlman KB, Pao W, Zhao Z. Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Genome Med. 2013; 5(10): 91. PMID: 24112718, PMCID: PMC3971343, PII: gm495, DOI: 10.1186/gm495, ISSN: 1756-994X.
Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, Netterville JL, Vnencak-Jones CL, Sosman JA, Ribas A, Zhao Z, Pao W. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov [print-electronic]. 2012 Sep; 2(9): 791-7. PMID: 22798288, PMCID: PMC3449158, PII: 2159-8290.CD-12-0097, DOI: 10.1158/2159-8290.CD-12-0097, ISSN: 2159-8290.
Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov [print-electronic]. 2012 May; 2(5): 414-24. PMID: 22588879, PMCID: PMC3594852, PII: 2159-8290.CD-12-0022, DOI: 10.1158/2159-8290.CD-12-0022, ISSN: 2159-8290.
Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A. RAF265 inhibits the growth of advanced human melanoma tumors. Clin. Cancer Res [print-electronic]. 2012 Apr 4/15/2012; 18(8): 2184-98. PMID: 22351689, PMCID: PMC3724517, PII: 1078-0432.CCR-11-1122, DOI: 10.1158/1078-0432.CCR-11-1122, ISSN: 1078-0432.
Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012; 3: 724. PMID: 22395615, PMCID: PMC3530385, PII: ncomms1727, DOI: 10.1038/ncomms1727, ISSN: 2041-1723.
Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS ONE [print-electronic]. 2012; 7(4): e35309. PMID: 22536370, PMCID: PMC3335021, PII: PONE-D-12-03589, DOI: 10.1371/journal.pone.0035309, ISSN: 1932-6203.
Dahlman KB, Parker JS, Shamu T, Hieronymus H, Chapinski C, Carver B, Chang K, Hannon GJ, Sawyers CL. Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. PLoS ONE [print-electronic]. 2012; 7(4): e34414. PMID: 22509301, PMCID: PMC3324507, PII: PONE-D-11-18538, DOI: 10.1371/journal.pone.0034414, ISSN: 1932-6203.
Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Dec 12/15/2011; 480(7377): 387-90. PMID: 22113612, PMCID: PMC3266695, PII: nature10662, DOI: 10.1038/nature10662, ISSN: 1476-4687.
Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL. FAS and NF-¿B signalling modulate dependence of lung cancers on mutant EGFR. Nature. 2011 Mar 3/24/2011; 471(7339): 523-6. PMID: 21430781, PMCID: PMC3541675, PII: nature09870, DOI: 10.1038/nature09870, ISSN: 1476-4687.
Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010 Dec 12/14/2010; 18(6): 683-95. PMID: 21156289, PMCID: PMC3026446, PII: S1535-6108(10)00484-8, DOI: 10.1016/j.ccr.2010.11.023, ISSN: 1878-3686.
Brown KA, Ham AJ, Clark CN, Meller N, Law BK, Chytil A, Cheng N, Pietenpol JA, Moses HL. Identification of novel Smad2 and Smad3 associated proteins in response to TGF-beta1. J. Cell. Biochem. 2008 Oct 10/1/2008; 105(2): 596-611. PMID: 18729074, PMCID: PMC2700048, DOI: 10.1002/jcb.21860, ISSN: 1097-4644.
Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J. Cell. Biochem. 2007 May 5/1/2007; 101(1): 9-33. PMID: 17340614, DOI: 10.1002/jcb.21255, ISSN: 0730-2312.
Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, Moses HL, Cheng N. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol. Ther. 2007 Apr; 6(4): 561-70. PMID: 17495520, PMCID: PMC3395216, PII: 3851, ISSN: 1538-4047.
Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res. 2006 Aug 8/1/2006; 66(15): 7589-97. PMID: 16885358, PII: 66/15/7589, DOI: 10.1158/0008-5472.CAN-06-2020, ISSN: 0008-5472.
Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene. 2005 Jul 7/28/2005; 24(32): 5053-68. PMID: 15856015, PMCID: PMC3074577, PII: 1208685, DOI: 10.1038/sj.onc.1208685, ISSN: 0950-9232.
Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia. 2004 Sep; 6(5): 603-10. PMID: 15548370, PMCID: PMC1531665, DOI: 10.1593/neo.04241, ISSN: 1522-8002.
Brown K, Bhowmick NA. Linking TGF-beta-mediated Cdc25A inhibition and cytoskeletal regulation through RhoA/p160(ROCK) signaling. Cell Cycle [print-electronic]. 2004 Apr; 3(4): 408-10. PMID: 14752278, PII: 778, ISSN: 1538-4101.
Brown KA, Aakre ME, Gorska AE, Price JO, Eltom SE, Pietenpol JA, Moses HL. Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res [print-electronic]. 2004; 6(3): R215-31. PMID: 15084245, PMCID: PMC400675, PII: bcr778, DOI: 10.1186/bcr778, ISSN: 1465-542X.
Brown KA, Roberts RL, Arteaga CL, Law BK. Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein. Breast Cancer Res [print-electronic]. 2004; 6(2): R130-9. PMID: 14979923, PMCID: PMC400660, PII: bcr762, DOI: 10.1186/bcr762, ISSN: 1465-542X.
Bhowmick NA, Ghiassi M, Aakre M, Brown K, Singh V, Moses HL. TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proc. Natl. Acad. Sci. U.S.A [print-electronic]. 2003 Dec 12/23/2003; 100(26): 15548-53. PMID: 14657354, PMCID: PMC307605, PII: 2536483100, DOI: 10.1073/pnas.2536483100, ISSN: 0027-8424.
Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem. Biophys. Res. Commun. 1997 Dec 12/18/1997; 241(2): 270-4. PMID: 9425261, PII: S0006-291X(97)97798-6, DOI: 10.1006/bbrc.1997.7798, ISSN: 0006-291X.